[
    [
        {
            "time": "",
            "original_text": "医药行业中期策略：配置业绩改善、估值合理的细分龙头标的",
            "features": {
                "keywords": [
                    "医药行业",
                    "中期策略",
                    "业绩改善",
                    "估值合理",
                    "细分龙头"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "医药行业中期策略：配置业绩改善、估值合理的细分龙头标的",
                "Correlation": 7,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 5,
                "Duration": 8,
                "Entity_Density": 3,
                "Market_Scope": 9,
                "Time_Proximity": 6,
                "Headline_Structure": 6,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "华兰生物今日大宗交易成交10.50万股，成交价31.6元折价9.92%",
            "features": {
                "keywords": [
                    "华兰生物",
                    "大宗交易",
                    "成交价",
                    "折价"
                ],
                "sentiment_score": -0.4,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "华兰生物今日大宗交易成交10.50万股，成交价31.6元折价9.92%",
                "Correlation": 9,
                "Sentiment": 4,
                "Importance": 6,
                "Impact": 5,
                "Duration": 4,
                "Entity_Density": 8,
                "Market_Scope": 3,
                "Time_Proximity": 10,
                "Headline_Structure": 7,
                "Source_Recency": 10
            }
        },
        {
            "time": "",
            "original_text": "生物制品:创新CAR-T疗法获批开启美国临床试验",
            "features": {
                "keywords": [
                    "生物制品",
                    "CAR-T疗法",
                    "获批",
                    "美国临床试验"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药",
                    "生物科技"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "生物制品:创新CAR-T疗法获批开启美国临床试验",
                "Correlation": 8,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 8,
                "Duration": 9,
                "Entity_Density": 5,
                "Market_Scope": 7,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        }
    ]
]